| _version_ | 1866901106953551872 |
|---|---|
| author | Nabaneeta Smaraki1, Harsh Rajeshbhai Jogi2, Bhavinkumar Pankajbhai Katira3# |
| author_facet | Nabaneeta Smaraki1, Harsh Rajeshbhai Jogi2, Bhavinkumar Pankajbhai Katira3# |
| contents | <p>Empty viral capsids vaccines, which are also termed Virus-like particles (VLPs), lack nucleic acid. VLPs offer various advantages, high safety and efficacy, enhanced DIVA capability, reduced need for a biosafety level III facility, and economy. Technology presents an alternative platform for developing effective vaccines to combat infectious diseases of serious concern, and it is moving in parallel with mRNA and viral-vector based vaccines. Empty capsid vaccines present repetitive antigenic epitopes on their surface in a more authentic confirmation that the immune system can readily detect these antigens. <span lang="EN-US">Chimeric VLPs are also produced which </span>display foreign peptide antigens from other infectious agents. <span lang="EN-US">Cloning viral structural genes of interest, </span>expression in prokaryotic or eukaryotic system, harvesting, purification and vaccine formulation are important steps in ECVs production. <span lang="EN-US">Various expression systems are available and newer methods of production are being explored. </span>Various products such as VLPs based hepatitis B and human papillomavirus vaccines have been delivered to the market. Although many advantages, technology suffer many challenges, mitigation of these challenges is important prospect of empty capsid vaccines technology.</p> <p> </p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_18048461 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | From Needles to Nanocarriers: Recent Advances in Vaccine Delivery Technologies Nabaneeta Smaraki1, Harsh Rajeshbhai Jogi2, Bhavinkumar Pankajbhai Katira3# <p>Empty viral capsids vaccines, which are also termed Virus-like particles (VLPs), lack nucleic acid. VLPs offer various advantages, high safety and efficacy, enhanced DIVA capability, reduced need for a biosafety level III facility, and economy. Technology presents an alternative platform for developing effective vaccines to combat infectious diseases of serious concern, and it is moving in parallel with mRNA and viral-vector based vaccines. Empty capsid vaccines present repetitive antigenic epitopes on their surface in a more authentic confirmation that the immune system can readily detect these antigens. <span lang="EN-US">Chimeric VLPs are also produced which </span>display foreign peptide antigens from other infectious agents. <span lang="EN-US">Cloning viral structural genes of interest, </span>expression in prokaryotic or eukaryotic system, harvesting, purification and vaccine formulation are important steps in ECVs production. <span lang="EN-US">Various expression systems are available and newer methods of production are being explored. </span>Various products such as VLPs based hepatitis B and human papillomavirus vaccines have been delivered to the market. Although many advantages, technology suffer many challenges, mitigation of these challenges is important prospect of empty capsid vaccines technology.</p> <p> </p> |
| title | From Needles to Nanocarriers: Recent Advances in Vaccine Delivery Technologies |
| url | https://doi.org/10.5281/zenodo.18048461 |